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Background. In kidney transplantation, chronic allograft
nephropathy (CAN) is the major cause of graft loss. Causes
of CAN include chronic rejection and chronic cyclosporine A
(CsA) nephrotoxicity. It is necessary to differentiate between
these two entities in order to apply the appropriate therapeutic
regimen for the individual patient, but this is hampered by the
lack of discriminating functional and morphologic parameters.
We investigated whether renal cortical mRNA levels for several
matrix proteins can serve as discriminating parameters.
Methods. Patients with chronic rejection (N =19) and chronic
CsA toxicity (N = 17) were selected by clinical and histo-
logic criteria. Protocol biopsies without histologic abnormal-
ities, taken at 6 months after transplantation from patients
receiving CsA, were used as controls (N = 6). Total RNA was
extracted from the renal biopsy tissue, and mRNA levels of
transforming growth factor-b (TGF-b) and the extracellular
matrix (ECM) molecules collagen Ia1, IIIa1, IVa3, decorin,
fibronectin, and laminin b2 were measured by real-time poly-
merase chain reaction (PCR).
Results. In both patient groups, the mean collagen IVa3 and
fibronectin mRNA levels were significantly elevated compared
to those in controls, whereas only in CsA toxicity were the
laminin b2 and TGF-b mRNA levels significantly increased.
The increase of laminin b2 and TGF-b mRNA levels was sig-
nificantly higher in the CsA toxicity group than in the chronic
rejection group (P < 0.001 and P = 0.004, respectively).
Receiver-operating characteristic (ROC) curve analysis showed
that with a 15.6-fold increase in laminin b2 mRNA expression
as cut-off point, the presence of CsA toxicity could be predicted
with an 87% sensitivity and an 88% specificity.
Conclusion. Renal laminin b2 and TGF-b mRNA levels can
be used to differentiate between chronic rejection and chronic
CsA toxicity in renal transplants. The method of mRNA quan-
tification might be applicable as an additional diagnostic tool in
clinical practice.
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Over the past decade, renal transplantation has be-
come a very successful treatment modality for end-stage
renal disease (ESRD). Due to improvement of immuno-
suppressive therapy, acute rejection episodes can be
treated effectively, and the prevalence of early graft loss
has diminished significantly [1]. Long-term graft loss,
however, currently forms a major problem in renal trans-
plantation [1–3].
The term chronic allograft nephropathy (CAN) refers
to the pathologic changes, including interstitial fibrosis,
tubular atrophy, and fibrous intimal thickening, which are
found in chronically dysfunctioning kidney transplants
[2]. Several risk factors for CAN have been recognized,
such as the number and the severity of acute rejection
episodes [4], ongoing chronic rejection, and excessive ex-
posure to calcineurin inhibitors such as cyclosporine A
(CsA) [2, 5]. Therefore, the lesions that occur in biopsies
of patients with CAN may result from either one or a
combination of these factors. Paradoxically, changes in-
duced by chronic rejection are clinically and histopatho-
logically hard to distinguish from those caused by the
nephrotoxic effects of chronic exposure to CsA, meant
to prevent chronic rejection. This makes it difficult to
determine the optimal dose of the immunosuppressive
regimen, in which the beneficial and nephrotoxic effects
of CsA are balanced [6].
Some changes observed in routine light microscopy
may help reveal the cause of chronic renal allograft
dysfunction. These include peripheral nodular arteriolar
hyalinosis, suggestive of chronic CsA toxicity, and trans-
plant vasculopathy (intimal fibrosis, disruption of the lam-
ina elastica in the presence of inflammation), suggestive
of chronic rejection [7, 8]. However, these lesions are
not decisively present in all patients with either of the
diagnoses. Furthermore, due to the fact that peripheral
nodular arteriolar hyalinosis and transplant vasculopathy
appear focally in the tissue, sampling errors may obscure
their presence.
In this study, we describe how differentiation be-
tween chronic rejection and chronic CsA toxicity may be
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improved with the aid of molecular techniques, based on
the results of a quantitative analysis of the renal cortical
mRNA levels of several extracellular matrix (ECM) com-
ponents and the ECM-regulating molecule transforming
growth factor-b (TGF-b) in two groups of patients suf-
fering from either disease entity.
We focused on several molecules that make up the in-
terstitial compartment of the kidney and are known to
accumulate in renal fibrosis, including collagens I and
III, and fibronectin, together with the ECM-regulating
molecule TGF-b and its potential inhibitor decorin. In
recent publications, attention has been drawn to expres-
sion of collagen IVa3 and laminin b2 in the discrimi-
nation between chronic rejection and CsA toxicity [9].
These molecules are also the subject of the current study.
METHODS
Patient populations
We reviewed all kidney transplant biopsies performed
in our center over the past 20 years, taken because of
renal function loss beyond 1 year after transplantation.
We selected two groups of patients: the chronic rejection
group and the chronic CsA toxicity group.
The chronic rejection group (N = 19), consisted of pa-
tients who received either prednisone and azathioprine
(N = 6), or prednisone and CsA (N = 13). Of the 13
patients using CsA, seven received the Sandimmune for-
mulation and six received the Neoral formulation. These
patients, with an initially well-functioning kidney trans-
plant, developed a progressive decline in renal function.
A biopsy was taken 4.8 ± 3.8 years after transplantation,
in which transplant vasculopathy (intimal fibrosis, inti-
mal inflammation, and disruption of the lamina elastica),
transplant glomerulopathy [characterized by double con-
tours of the glomerular basement membrane (GBM)]
or both were present as a histopathologic indication of
chronic rejection, as defined by the Banff 97 classification
[7]. Biopsies with peripheral nodular arteriolar hyalinosis,
a lesion suggestive of CsA toxicity, and biopsies with signs
of de novo or recurrent native disease were excluded.
Patients suffering from diabetes and patients with graft
arterial stenosis were excluded.
The chronic CsA toxicity group (N = 17), consisted of
patients with an initially well-functioning kidney trans-
plant, who developed a progressive decline in renal func-
tion only after a switch was made from Sandimmune
to Neoral; CsA formulations with a relatively low and
a relatively high bioavailability, respectively. Before the
switch, immunosuppression was aimed at CsA 24-hour
trough levels of 100 lg/L by administration of Sandim-
mune once daily. After the switch, Neoral was admin-
istered twice daily, aiming at a 12-hour trough level of
150 lg/L. Thereby, the mean daily CsA dose was in-
creased from 3.2 mg/kg to 3.5 mg/kg [10]. Patients who
developed a significant and progressive decrease in renal
function after this switch, in the absence of other fea-
tures that might explain the decline in renal function,
were included. Renal biopsies, taken 7.1 ± 3.4 years after
transplantation and 2.5 ± 1.2 years after the switch from
Sandimmune to Neoral, showed peripheral nodular arte-
riolar hyalinosis in 16 of the 17 patients, histopatholog-
ically supporting the functional selection. Biopsies with
histologic features suggestive of chronic rejection or de
novo or recurrent glomerulonephritis were excluded. Pa-
tients suffering from diabetes and patients with graft ar-
terial stenosis were excluded.
C4d staining was performed on all biopsy samples.
None of the patients in the CsA toxicity group showed
C4d depositions in their peritubular capillaries, while
26% of the patients in the chronic rejection showed dif-
fuse C4d depositions in the peritubular capillaries.
Control group
As controls (N = 6), we used protocol transplant biop-
sies taken from patients at 6 months after transplantation
with stable graft function at the time of biopsy. Apart
from some cases showing signs of minor nonspecific age-
related alterations, none of the biopsies showed any signs
of rejection or drug toxicity. The glomeruli (at least ten
present in the sections for evaluation) did not show any
abnormalities. Patients in this control group all used CsA
as immunosuppressive medication.
Clinical data
Clinical data included gender, patient age at time of
biopsy, donor age, transplant-origin (cadaveric or liv-
ing donor), number of acute rejection episodes, delayed
graft function, time between transplantation and biopsy,
time between switch and biopsy, mean arterial pressure
(MAP), number of antihypertensive drugs used, use of
angiotensin-converting enzyme (ACE) inhibitors, lowest
serum creatinine, serum creatinine at biopsy, proteinuria
at time of biopsy, and CsA trough levels. We estimated
the best endogenous creatinine clearance and creatinine
clearance at biopsy using the Cockcroft-Gault equation
[11]. The loss of renal function was defined as the best
Cockcroft clearance minus the Cockcroft clearance at the
time of biopsy.
mRNA isolation and cDNA synthesis
Four micrometer cryostat sections of each biopsy were
cut, air dried, and stored at −20◦C until use for immuno-
histochemistry. One section was evaluated to localize the
cortex, which was thereafter excised from the biopsy.
RNA was subsequently extracted, as described previ-
ously [12]. In brief, the tissue was lysed by rigorous mix-
ing after suspension in 500 lL TRIzol (Invitrogen Life
Technologies, Carlsbad, CA, USA). After adding 100 lL
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Table 1. Primer and probe sequences
Molecule Forward primer Reverse primer TaqManTM probe
GAPDH TGG TCA CCA GGG CTG
CTT
AGC TTC CCG TTC TCA
GCC TT
5′-FAM-TCA ACT ACA TGG TTT ACA TGT TCC AAT
ATG ATT CCA CCA A-TAMRA-3′
b 2m TGC CGT GTG AAC CAT
GTG A
CCA AAT GCG GCA TCT
TCA A
5′-TET-TGA TGC TGC TTA CAT GTC TCG ATC CCA
CT-TAMRA-3′
HPRT1 TGA CAC TGG CAA AAC
AAT GCA
GGT CCT TTT CAC CAG
CAA GCT
5′-TET-CTT GAC CAT CTT TGG ATT ATA CTG CCT
GAC CA-TAMRA-3′
Collagen Ia1 CCT CAA GGG CTC CAA
CGA G
TCA ATC ACT GTC TTG
CCC CA
5′-TET-ATG CCT GCA CGA GTC ACA CCG
GA-TAMRA-3′
Collagen IIIa1 GAG GAT GGT TGC ACG
AAA CA
TGT CAT AGG GTG CAA
TAT CTA CAA TAG G
5′-TET-TGA ATA TCG AAC ACG CAA GGC TGT GAG
ACT-TAMRA-3′
Collagen IVa3 AAG CCC ACC ACA TGA
TTC TGA
GCA GTT GTA GCC AGC
CGT ACT
5′-FAM-TCC AAG CAC ACT CCG CAG GCA
GT-TAMRA-3′
Decorin ACA TCC GCA TTG CTG
ATA CCA
AGT CCT TTG AGG CTA
GCT GCA TC
5′-FAM-TCA CCA GCA TTC CTC AAG GTC TTC CTC
C-TAMRA-3′
Fibronectin GGA GAA TTC AAG TGT
GAC CCT CA
TGC CAC TGT TCT CCT
ACG TGG
5′-TET-AGG CAA CGT GTT ACG ATG ATG GGA AGA
CAT-TAMRA-3′
Laminin b2 GGA TGA GGC TCG GGA
CCT
CCC GTC CAA CTG GGC
TG
5′-TET-AGG AAT TGG AAG GCA CCT ATG AGG AAA
ATG A-TAMRA-3′
TGF-b1 CCC AGC ATC TGC AAA
GCT C
GTC AAT GTA CAG CTG
CCG CA
5′-TET-ACA CCA ACT ATT GCT TCA GCT CCA CGG
A-TAMRA-3′
Abbreviations are: GAPDH, glyceraldehyde-3-phosphate dehydrogenase; b 2m, b 2-microglobulin; HPRT1, hypoxanthine phosphoribosyl-transferase 1; TGF-b ,
transforming growth factor-b ; TET, 6-carboxy-4,7,2′,7′-tetrachloro-fluorescein; FAM, 6-carboxy fluorescein; TAMRA, 6-carboxy-tetramethyl-rhodamine.
chloroform, the solution was centrifuged at 15,000g for
15 minutes. The RNA was precipitated by addition of
5 lg of glycogen and 250 lL isopropanol. cDNA synthe-
sis was performed using an reverse transcription (RT)
kit (Omniscript Reverse Transcriptase) (Qiagen GmbH,
Westburg B.V., The Netherlands).
Real-time polymerase chain reaction (PCR)
For several ECM molecules and TGF-b1, forward and
reverse primers (Life Technologies BRL and Biosource
International, Nivelles, Belgium) and TaqManTM probes
(Biosource International) were designed, using Primer
Express 1.5 software (PE Applied Biosystems, Foster
City, CA, USA). To prevent amplification of genomic
DNA, primers or probes were chosen spanning an exon-
intron junction. Primers were located near the 3′ end of
the mRNA. The 5′ ends of the TaqmanTM probes were 6-
carboxy-4,7,2′,7′-tetrachloro-fluorescein (TET)-labeled,
except those for glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH), collagen IVa3, and decorin, which were
6-carboxy fluorescein (FAM)-labeled. The quencher dye
at the 3′ side of the probe was 6-carboxy-tetramethyl-
rhodamine (TAMRA). The sequences of the primers and
of the TaqManTM probes are shown in Table 1.
Real-time PCR was performed using the ABI PrismTM
7700 sequence detector and software (PE Applied
Biosystems) [13]. Amplification cycles were 95◦C for
10 minutes, followed by 40 cycles at 95◦C for 30 sec-
onds and at 60◦C for 60 seconds. Kinetics of the reac-
tions were determined using a standard curve. We used
the ratio of the levels of the investigated molecule and
GAPDH, a constitutively expressed gene, to correct for
the amount of tissue used for RNA extraction and the
efficiency of cDNA synthesis. To confirm the suitabil-
ity of GAPDH as a housekeeping gene, we tested the
correlation between the expression of two additional
housekeeping genes [i.e., hypoxanthine phosphoribosyl
transferase 1 (HPRT1) and b 2-microglobulin (b 2m)], and
that of GAPDH in all samples.
Immunofluorescence for C4d
Immunofluorescence staining for C4d was performed
on untreated slides using standard procedures as de-
scribed before [14, 15]. As the primary antibody, mouse
anti-C4d antibody (Quidel, San Diego, CA, USA), di-
luted to 2 ng/mL in phosphate-buffered saline (PBS)
and supplemented with 1% bovine serum albumin
(BSA), was used. The secondary antibody was fluorescein
isothiocyanate (FITC)-conjugated goat anti-mouse IgG
(Sigma Chemical Co., St. Louis, MO, USA), diluted 1:200
in BSA/PBS. The staining was evaluated independently
by two of the authors (K.K. and M.E.), blinded for the di-
agnosis of the samples. C4d staining was observed in the
peritubular capillaries (PTC) in a circumferential pattern.
Sporadically, mesangial and GBM areas of the glomeru-
lus stained positive. In accordance with scoring methods
described in the literature on C4d deposition in renal al-
lografts [16, 17], biopsies were scored C4d-positive when
more than 25% of the PTC showed an intense and circum-
ferential staining as depicted in Figure 1. In most cases
of diffuse positive samples all PTC were affected. In the
few cases of discordant scoring, decision was reached by
consensus.
Immunohistochemistry
For evaluation of protein expression in the tissue, im-
munohistochemistry was performed for laminin b2 and
TGF-b . Four micrometer frozen sections were thawed,
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Fig. 1. Immunofluorescence staining for C4d. In some chronic rejec-
tion samples diffuse circumferential staining of peritubular capillaries
for C4d was observed (original magnification × 400).
air dried, and incubated for 1 hour with mouse mono-
clonal anti-laminin b2 antibodies (Developmental Stud-
ies Hybridoma Bank, Iowa City, IA, USA) diluted 1:16
in BSA/PBS, or rabbit polyclonal anti-TGF-b (Dako,
Glostrup, Denmark), diluted 1:400 in BSA/PBS. The anti-
TGF-b antibodies stain both the active and latent form
of TGF-b . The slides were washed in PBS, and subse-
quently incubated with horseradish peroxidase (HRP)-
conjugated antimouse Envision and HRP-conjugated
antirabbit Envision, respectively (Dako). After 45 min-
utes of incubation, the slides were washed in PBS and the
staining was developed with diaminobenzidine (DAB).
The color was enhanced by incubating the slides in 0.5%
CuSO4 solution for 5 minutes. After counterstaining with
hematoxylin, the slides were dehydrated and mounted.
For each staining, all biopsy samples were stained in one
session.
Digital image analysis
To quantify the amount of staining for TGF-b and
laminin b2, images of the cortical part of the biopsies
were taken at a 200× magnification using a Zeiss mi-
croscope equipped with a Sony DXC-950P 3 CCD color
camera (Sony Corporation, Tokyo, Japan) and further an-
alyzed using KS-400 image analysis software (version 3.0
for Windows) (Carl Zeiss Vision GmbH, Oberkochen,
Germany). The cortical area stained was defined as the
amount of staining within the color spectrum specific for
the enhanced DAB staining, and above a fixed intensity
threshold, as described previously [18]. Recording and
analysis of the images were performed with fixed settings.
Statistical analysis
Statistical analysis was performed using SPSS 10.0.7
for Windows software. We used log transformed (10log)
mRNA levels for analysis. A one-way analysis of vari-
Table 2. Clinical characteristics of the patient groups and the control
groupa
Chronic
Chronic cyclosporine
Group rejection A toxicity Controls
Number 19 17 6
Gender female 10 (53%) 4 (24%) 2 (33%)
Number of patients treated
with cyclosporine A
13 (68%) 17 (100%) 6 (100%)
Patient age years ± SD 44 ± 14 49 ± 13 45 ± 6
Donor age years ± SD 35 ± 16 44 ± 10 47 ± 17
Living-donor kidney
transplants %
5 35c
Number of acute rejection
episodes
0.8 ± 1.0 0.5 ± 0.6
Delayed graft function % 21 18
Time between transplantation
and biopsy years ± SD
4.8 ± 3.8 7.1 ± 3.4
Time between switch and
biopsy years ± SD
2.5 ± 1.2
Mean arterial pressure 108 ± 10 106 ± 8
Number of antihypertensive
drugs used (0/1/2/≥3)
2/2/8/7 2/5/5/5
Use of angiotensin-converting
enzyme inhibitors %
21 29
Best serum creatinine level
lmol/L ± SD
113 ± 27 124 ± 25
Serum creatinine at time of
biopsy lmol/L ± SD
238 ± 83 201 ± 45 118 ± 25
Best creatinine clearance
mL/min ± SD
74 ± 22c 61 ± 11
Creatinine clearance at time of
biopsy mL/min ± SD
36 ± 14 40 ± 15 68 ± 14
Loss of renal function lmol/L
± SDb
38 ± 16d 21 ± 13
Proteinuria at time of biopsy
g/24 hours ± SD
2.9 ± 2.6 1.3 ± 1.5
Cyclosporine A trough levels
at time of biopsy lg/L ± SD
110 ± 31 114 ± 30
aCreatinine clearance was estimated by the Cockcroft-Gault equation.
bLoss of renal function was defined as the difference between the best
creatinine clearance and the creatinine clearance at the time of biopsy.
cP < 0.05; dP < 0.01.
ance (ANOVA) with a Bonferroni post hoc correction
was used for comparison of differences between groups.
Using a receiver-operating characteristic (ROC) curve,
we determined the cut-off point of mRNA levels with
the best combination of sensitivity and specificity that
predicted the presence of CsA toxicity. Correlations be-
tween the mRNA data and the clinical characteristics of
the patient groups were calculated using Pearson’s cor-
relation test. P < 0.05 was considered statistically signif-
icant.
RESULTS
Patient data
The clinical characteristics of the patients and the con-
trols are listed in Table 2. Renal function at time of
biopsy, donor age, patient age, number of acute rejec-
tion episodes, delayed graft function, the time interval
between transplantation and biopsy, MAP, number of
antihypertensive drugs used, and use of ACE inhibitors
did not differ significantly between patient groups. There
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Table 3. Log transformed mRNA levelsa
Total chronic Chronic rejection using Chronic cyclosporine
rejection (Ia)b cyclosporine A (Ib)b,c A toxicity (II)b Controls (III)
Collagen Ia1 0.3 ± 0.2 0.2 ± 0.3 0.2 ± 0.3 0.8 ± 0.2
Collagen IIIa1 0.3 ± 0.2 0.2 ± 0.2 0.3 ± 0.2 0.3 ± 0.1
Collagen IVa3 0.1 ± 0.2d 0.1 ± 0.2d 0.5 ± 0.1d −1.9 ± 0.3
Decorin 0.0 ± 0.2 −0.2 ± 0.2 −0.1 ± 0.2 −0.4 ± 0.2
Fibronectin −0.1 ± 0.2d −0.3 ± 0.2d −0.1 ± 0.2d −1.6 ± 0.2
Laminin b2 0.6 ± 0.1f 0.5 ± 0.2‡ 1.1 ± 0.1d −0.1 ± 0.3
Transforming growth factor-b 0.8 ± 0.1e 0.8 ± 0.2e 1.3 ± 0.1d 0.5 ± 0.2
Ratio transforming growth factor-b/decorin 0.8 ± 0.2e 0.8 ± 0.2e 1.4 ± 0.1 0.9 ± 0.2
aAll values are mean ± SEM.
bP < 0.05, I or II vs. III.
cMean log transformed mRNA levels of the chronic rejection group after omission of patients using azathioprine as immunosuppression.
dP < 0.01, I or II vs. III.
eP < 0.05, I vs. II.
fP < 0.01, I vs. II.
was significantly greater loss of renal function in the
chronic rejection group than in the chronic CsA toxic-
ity group (38 ± 16 mL/min and 21 ± 13 mL/min, respec-
tively) (P < 0.01). There were significantly more patients
with a living-donor kidney transplant in the CsA toxicity
group, compared with the chronic rejection group (35%
and 5%, respectively) (P = 0.02).
Cortical mRNA levels
GAPDH mRNA levels did not differ between groups
(data not shown). Within the chronic rejection group,
mean GAPDH expression did not significantly differ
between CsA-using and non-CsA–using patients. There
was a significant correlation between GAPDH mRNA
and mRNA of the two other housekeeping molecules
measured (r = 0.74 and r = 0.92 for b 2m and HPRT1,
respectively) (P < 0.001). Additionally, we tested com-
parisons between the chronic rejection and the CsA
toxicity group for all transcripts using b 2m as the house-
keeping molecule. This yielded the same results as when
GAPDH was used. These findings support the suitability
of GAPDH as a housekeeping molecule in the experi-
ments.
The mean log transformed mRNA levels of collagen
Ia1, collagen IIIa1, collagen IVa3, decorin, fibronectin,
laminin b2, and TGF-b are shown in Table 3 and de-
picted in Figure 2. The mRNA levels of collagen IVa3
and fibronectin were higher in both patient groups com-
pared to controls. The mRNA levels of laminin b2 and
TGF-b were higher in the CsA toxicity groups compared
to controls (Table 3) (Fig. 2F and H). The renal mRNA
levels of collagen Ia1, IIIa1, and IVa3, decorin, and
fibronectin were not significantly different between pa-
tients with chronic rejection and patients with CsA toxi-
city (Table 3) (Fig. 2A to E). The renal mRNA levels of
laminin b2, TGF-b , and the ratio of TGF-b to decorin
were significantly higher in patients with CsA toxicity
than in patients with chronic rejection (Table 3) (Fig. 2F
and G). After omitting patients who did not use CsA
from the chronic rejection group, comparative analyses
between groups yielded comparable results (Table 3). In
addition, there were no differences in mRNA expression
of all molecules analyzed between chronic rejection pa-
tients who used CsA and those who did not use CsA
as immunosuppression (collagen Ia1, P = 0.44; collagen
IIIa1, P = 0.51; collagen IVa3, P = 0.57; decorin, P =
0.07; fibronectin, P = 0.10; laminin b2, P = 0.52; TGF-
b , P = 0.53). There were no significant differences be-
tween mRNA expression levels in cadaveric transplants
and living-donor transplants within each patient group.
Immunohistochemistry
We performed immunohistochemical stainings to eval-
uate the tissue expression of laminin b2 and TGF-b at the
protein level (Fig. 3). In biopsies of controls, laminin b2
staining was observed in the GBM and in cortical vessels
(Fig. 3A). In chronic rejection as well as in CsA toxicity,
sporadic expression of laminin b2 was seen in the tubu-
lar basement membrane (Fig. 3B and C). TGF-b stain-
ing was sporadically observed in glomeruli and tubuli of
controls (Fig. 3D). In sections of biopsies from patients
suffering from chronic rejection or CsA toxicity, some
tubuli showed very intense staining for TGF-b (Fig. 3E
and F). There was no relation between this sporadic in-
tensive staining and mRNA expression levels or clinical
parameters.
In both patient groups, the amount of laminin b2 stain-
ing was increased compared to controls. The mean corti-
cal area percentage was slightly higher in the CsA toxicity
group than in the chronic rejection group (5.7 ± 1.5 and
5.3 ± 1.0, mean ± SEM) (Fig. 4A). The differences be-
tween groups were not significant. The amount of TGF-b
staining was higher in patient groups than in controls.
The mean cortical area percentage was higher in the CsA
toxicity group than in the chronic rejection group (15.8 ±
3.6 and 13.4 ± 2.2, mean ± SEM) (Fig. 4B), though this
difference did not reach statistical significance.
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Fig. 2. Box and whisker plots of the log transformed mRNA levels.
The boxes contain 50% of the values. The upper and lower border indi-
cate the 25th and the 75th percentile, respectively. The upper and lower
whisker indicate the highest and lowest value, respectively. The black
line in the box indicates the median and the (◦) indicates an outlier.
(A) Collagen Ia1. (B) Collagen IIIa1. (C) Collagen IVa3 [P < 0.001
chronic rejection (CR) and cyclosporine A (CsA) toxicity (CsAT) vs.
controls]. (D) Decorin. (E) Fibronectin (P < 0.001 chronic rejection
and CsA toxicity vs. controls. (F) Laminin b2 (P < 0.001 CsA toxicity
vs. controls) (P = 0.002 chronic rejection vs. CsA toxicity). (G) Trans-
forming growth factor-b (TGF-b) (P = 0.004 CsA toxicity vs. controls)
(P = 0.020 chronic rejection vs. CsA toxicity). (H) TGF-b/decorin ratio
(P = 0.014 chronic rejection vs. CsA toxicity).
ROC curve analysis
ROC curve analysis (Fig. 5) showed that a 15.6-fold in-
crease of laminin b2 mRNA levels compared to controls
indicates the presence of CsA toxicity with an 87% sensi-
tivity and an 88% specificity. The area under the curve was
0.90 (P < 0.001). Similarly, a ninefold increase of TGF-b
mRNA levels predicts the presence of chronic CsA tox-
A
B
C F
E
D
Fig. 3. Immunohistochemical stainings for laminin b2 (A to C) and
transforming growth factor-b (TGF-b) (D to F). In control tissue laminin
b2 staining was observed in the glomerular basement membrane and
in cortical vessels (A). In chronic rejection (B) and cyclosporine A
(CsA) toxicity (C), expression of laminin b2 was observed in the tubu-
lar basement membrane. TGF-b staining was sporadically observed in
glomeruli and tubuli of controls (D). In chronic rejection (E) and CsA
toxicity (F), some tubuli showed a very intense staining for TGF-b .
icity with a 60% sensitivity and an 88% specificity (area
under the curve 0.76) (P < 0.05).
Correlations
No correlations were found between mRNA levels and
age, donor age, number of acute rejection episodes, de-
layed graft function, time between transplantation and
biopsy, the time between switch and biopsy, loss of re-
nal function, MAP, and use of ACE inhibitors. Only in
the chronic rejection group, TGF-b mRNA levels and
the ratio of TGF-b to decorin mRNA levels correlated
significantly with laminin b2 mRNA levels (r = 0.56 and
r = 0.68, respectively) (P < 0.05).
DISCUSSION
This study was designed to enhance the discrimination
between chronic rejection and chronic CsA toxicity as a
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group compared to the chronic rejection group. There are no significant
differences between groups.
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Fig. 5. Receiver-operating characteristic (ROC) curve of laminin b2
and transforming growth factor-b (TGF-b). The fraction of true positive
results (sensitivity) and false positive results (1-specificity) for laminin
b2 (solid line) and TGF-b (dashed line) mRNA levels. The area under
the curve indicates the accuracy of the test: 0.5 is the value expected by
chance (diagonal line), 1.0 represents the ideal predictor. The area under
the curves for laminin b2 and TGF-b are 0.896 and 0.758, respectively.
Using a 15.6-fold increase in laminin b2 mRNA levels to those of normal
controls as cut-off point, the sensitivity is 87% and the specificity 88%
for the prediction of the presence of chronic cyclosporine A toxicity.
cause of CAN. With current clinical and histologic pa-
rameters this distinction is difficult to make because of
the similarities in clinical presentation and aspecificity
of the lesions in needle biopsies of patients with CAN.
We show that quantification of mRNA levels of laminin
b2 and TGF-b can be used to distinguish chronic rejec-
tion from CsA toxicity, which will help in fine-tuning the
immunosuppressive regimen. In this way, the beneficial
effects of CsA are not abrogated by its nephrotoxic side
effects [3].
In our center, we had the opportunity to define on
functional criteria a patient group that suffered from
chronic CsA toxicity, comprising patients who developed
a progressive decline in renal function after a change in
immunosuppressive medication was made leading to a
higher CsA exposure [10]. The appropriateness of these
selection criteria was supported by histopathologic find-
ings: peripheral nodular arteriolar hyalinosis, regarded as
a finding suggestive of CsA toxicity, was present in 94%
of these patients, and C4d deposition in PTCs, a feature
frequently seen in chronic rejection [19], was absent in
all patients of the CsA toxicity group. An additional se-
lection criterion for the CsA toxicity group and a further
proof of CsA toxicity might have been the recovery of
renal function after stopping or reducing CsA adminis-
tration. Unfortunately, these data were not available. In
the chronic rejection group, 13 out of 19 patients also re-
ceived CsA. However, since the CsA formulation in the
majority of these patients had a relatively low bioavail-
ability and administration was applied only once-daily,
this group is less likely to have suffered from CsA toxicity.
In addition, patients in this group had transplant vascu-
lopathy or glomerulopathy, histologic features suggestive
of chronic rejection, but they did not show histologic fea-
tures consistent with CsA toxicity. Finally, although there
was some heterogeneity in immunosuppressive medica-
tion in the chronic rejection group, no differences were
found in mRNA data between patients using CsA and
those who did not use CsA as immunosuppression, and
analysis with only the group of chronic rejection patients
using CsA as immunosuppression yielded the same re-
sults as the chronic rejection group as a whole. A strik-
ing difference in patient characteristics was that 35% of
the CsA toxicity group, but only 5% of the transplants in
the chronic rejection group were living donor transplants.
This might support the opinion that injuries inflicted to ca-
daveric allografts before or during transplantation elicit a
predisposition for the development of chronic rejection,
as has been suggested before [2, 20].
The ECM is a meshwork of proteins, in which remod-
eling continuously takes place by means of protein syn-
thesis and degradation. Accumulation of ECM proteins
reflects an imbalance of this dynamic process, resulting
from an increase in protein synthesis, a decrease in pro-
tein degradation, or a combination of both. The synthesis
of ECM components is enhanced by several profibrotic
cytokines, including TGF-b . During chronic renal allo-
graft dysfunction, this cytokine has been shown to be up-
regulated at the mRNA and protein level in the grafts,
sera, and peripheral blood mononuclear cells of patients
taking CsA-based immunosuppression [21, 22]. TGF-b
mRNA levels are up-regulated in cultured murine proxi-
mal tubular epithelial cells and fibroblasts after exposure
to CsA [23]. Moreover, in rats receiving CsA, administra-
tion of anti-TGF-b1 antibodies reduces the extent of his-
tologic damage reminiscent of CsA toxicity [24]. Decorin,
a low-molecular-weight proteoglycan, can bind and inac-
tivate TGF-b , thereby preventing its prosclerotic action
[25]. The TGF-b/decorin mRNA ratio may therefore be
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a better indicator of TGF-b activity than TGF-b mRNA
levels alone. We found a significant increase of TGF-b
mRNA levels and of the TGF-b/decorin ratio in CsA
toxicity, supporting the notion that CsA has a stimula-
tory effect on TGF-b expression.
Laminin b2 is a normal component of the renal vas-
culature and the GBM [26]. We observed an increase in
laminin b2 mRNA expression in the CsA toxicity group
compared to controls, the expression in the CsA toxicity
group being also significantly higher than in the chronic
rejection group. Laminin b2 mRNA expression was also
higher in the CsA toxicity group when comparing it to
the chronic rejection group with only those patients us-
ing CsA included. Only sparse information about factors
stimulating laminin b2 expression is available. The re-
sults of our study suggest a direct or indirect stimulatory
effect of CsA on laminin b2 expression, yet the underly-
ing mechanism is unclear.
We performed immunohistochemistry combined with
digital image analysis for laminin b2 and TGF-b to evalu-
ate the expression of these molecules at the protein level.
The pattern seen at the protein level resembled that at the
mRNA level (i.e., there was a tendency toward a higher
expression of laminin b2 and TGF-b in the CsA toxic-
ity group than in the chronic rejection group). However,
differences in protein staining between groups did not
reach statistical significance. Furthermore, a correlation
between mRNA expression levels and protein deposi-
tion was absent. The observation that the extent of pro-
tein accumulation does not strictly coincide with mRNA
levels has been described before [27]. Additionally, in
vivo accumulation of protein is not only determined by
synthesis, but also by degradation of ECM products. Al-
though we did not evaluate the mechanism of laminin
b2 degradation, the notion that laminin b2 mRNA lev-
els were increased in the CsA toxicity group compared
to the chronic rejection group, while protein levels were
not significantly different, might suggest that there is an
increased degradation of laminin b2 in CsA toxicity. This
might be due to the microvascular damage exerted by
CsA [8].
Collagen Ia1 and collagen IIIa1 are components of the
renal interstitium that are normally present in relatively
small amounts [28]. Accumulation of these molecules has
been reported in a variety of chronic human kidney dis-
eases [29] and CAN [30, 31]. There was no difference be-
tween the chronic rejection group and the CsA toxicity
group in collagens I and III mRNA levels. We observed
no differences in the mRNA levels between the patient
groups and the control group. This might be explained by
the possibility that the accumulation of collagens I and
III in CAN is a result of an early increase in collagen
synthesis that might have taken place before the overt
damage seen in the tissues. Furthermore, it might be that
the accumulation of collagens I and III in patients with
CAN is due to an impaired degradation of these proteins,
as has been suggested before [32].
Collagen IVa3 is a component of both the GBM and
the distal tubular basement membrane (TBM) [26]. In a
study by Abrass et al [9], de novo expression of colla-
gen IVa3 protein was reported in the proximal TBM in
chronic rejection, but not in CsA toxicity. In our study, we
did not observe significant differences in collagen IVa3
mRNA expression levels between the two groups. Since
we used total cortical tissue for mRNA analysis, it is pos-
sible that subtle differences of collagen IVa3 mRNA
expression in the proximal tubulus epithelium between
patient groups remained undetected. When we focused
only on the chronic rejection group, the collagen IVa3
mRNA expression was higher in the C4d+ chronic re-
jection group than in the C4d– chronic rejection group
(data not shown). C4d recently has gained much interest
as a marker of humoral rejection, but there is only sparse
information about the relation between C4d and accu-
mulation of ECM [33]. Future studies would be needed
to decipher whether the relation found in our study is of
pathogenic significance.
In both the chronic rejection and the chronic CsA tox-
icity group, we observed a significant increase in renal
cortical fibronectin mRNA levels in comparison to con-
trols. There were no differences in the mRNA levels of
fibronectin between the chronic rejection and the CsA
toxicity group. This is in line with previous studies show-
ing an increase in fibronectin mRNA levels in a rat model
of CsA toxicity [34], and in allograft rejection, both at the
mRNA and the protein level [35, 36].
One of the advantages of analyzing mRNA profiles
may be that alterations in mRNA levels precede the de-
velopment or aggravation of tissue damage [37]. This
holds promise for an earlier recognition of an unfavorable
course after kidney transplantation [38, 39]. Furthermore,
quantitative mRNA analysis can be performed rapidly,
and requires only small amounts of renal tissue. In the
future, diagnostic approaches using molecular analysis
simultaneously with conventional strategies are likely to
be implemented in clinical practice [40]. We had the op-
portunity to compose merely on the basis of functional
variables two patient groups that represent the extremes
of a spectrum of causes leading to the development of
CAN. Therefore, we studied the presence of markers that
could discriminate between these two highly selected pa-
tient groups. An obvious prerequisite for implementation
in clinical practice is to test the use of these markers in
larger nonselected patient groups.
CONCLUSION
We measured human renal cortical mRNA expression
levels of ECM components in two well-defined groups of
patients suffering from either chronic rejection or chronic
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CsA toxicity. In both patient groups, the mean mRNA
levels for collagen IVa3 and fibronectin were significantly
elevated compared to those in controls, whereas in CsA
toxicity the laminin b2 and TGF-b mRNA levels were
also significantly increased. Most important, we showed
that laminin b2 and TGF-b mRNA levels are significantly
higher in patients with CsA toxicity than in patients with
chronic rejection, and that measurement of these expres-
sion levels may help differentiate chronic CsA toxicity
from chronic rejection.
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